Eli Lilly ($LLY) and its close diabetes drug development partner Boehringer Ingelheim laid out a slate of positive late-stage data for its diabetes treatment empagliflozin, a big step toward applying for regulatory approval this year. Report
Effective content harmonization requires a global system that can balance the needs of both the corporate office and satellite entities and partners. For companies considering content harmonization initiatives, this paper discusses best practices and the efficiency benefits they can expect from deploying a global system. Download now.
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!